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sive therapy may be considered in this subgroup.224
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The optimal timing of hematopoietic cell transplantation
(HCT) in AML is still under debate. We addressed this ques-
tion in the AML 2003 study, a large, multicenter, open-label,
randomized study of the German SAL group. All patients
received one cycle of induction therapy (IT). Upfront
molecular characterization, HLA typing and donor search
were performed. The transplant strategy was tailored to AML
risk and to donor availability. Patients aged 18-60 years were
randomly assigned upfront 1:1 to either one of two trans-
plant strategies: In the control arm HLA-identical sibling HCT
was scheduled in ﬁrst complete remission for patients with
intermediate cytogenetic risk AML and related or unrelated
compatible HCT for patients with a complex karyotype (CK).
In the experimental arm the indication for allogeneic HCT
was extended to patients with an FLT3-ITD allelic ratio >0.8
(mutant/wild type), >10% marrow blasts on day 15 after IT1
and patients with adverse karyotypes, including: -7, -5,
del(5q), inv(3q), t(3;3), t(6;9), t(6;11), t(11;19) (q23;p13.1).
Furthermore, HCT was scheduled earlier, i.e. in aplasia after
the ﬁrst or the second cycle of IT.
Between December 1st, 2003 and November 26th, 2009
1179 patients were assigned randomly either to the experi-
mental (N¼598) or the control intervention (N¼581). The
median age was 48 years (range, 18 to 60 years) and the
median observation time now is 52 months. In the intent-to-
treat analysis the hazard ratio of the treatment effect
(experimental versus control) was 0.92 (95% CI, 0.75 to 1.14;
P ¼ .45) for the primary endpoint overall survival (OS) and
0.85 (95% CI, 0.71 to 1.02; P¼ .08) for the secondary endpoint
event-free survival (EFS). However, the rate of patients who
received allogeneic HCT as ﬁrst post-remission therapy was
only 39% in the experimental arm and 20% in the control arm.
Thus, the analysis according to the intent-to-treat could not
discriminate appropriately between the two treatment
strategies. In an exploratory analysis, we therefore analyzed
the effect of allogeneic HCT as a time-dependent covariate in
a Cox-regressionmodel. We adjusted for the cytogenetic risk,age, ECOG performance status, white blood cell count, and
LDH at diagnosis. In this as-treated analysis the adjusted
hazard ratio for the treatment (allogeneic HCT versus
chemotherapy) was 0.73 (95% CI, 0.59 - 0.89; P ¼ .002) for OS
and 0.67 (95% CI, 0.55 - 0.82; P < .001) for EFS. This analysis
corrects appropriately for a classical time-selections bias.
However, a patient selection based on comorbidity or ﬁtness
cannot be ruled out.
In conclusion, a survival beneﬁt from early compared to
late allogeneic HCT could not be shown in the intent-to-treat
analysis of this large randomized trial using a risk-adapted
transplant strategy. However, the results of the as-treated
analysis suggest a substantial beneﬁt from allogeneic HCT in
ﬁrst remission versus chemotherapy.
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Mixed phenotype acute leukemia (MPAL) is a rare
leukemia with features of both myeloid and lymphoid
lineage. The 2008 World Health Organization (WHO) deﬁ-
nition of MPAL is based on the expression of strictly speciﬁc
T-lymphoid (cytoplasmic CD3) and myeloid (myeloperox-
idase) antigens, and B-cell lineage assignment relies on the
expression of CD19 together with other B celleassociated
markers (Borowitz et al. World Health Organization Classi-
ﬁcation of Tumours: Pathology and Genetics of Tumours of
Haematopoietic and Lymphoid Tissues. 2008). In this retro-
spective review, we analyzed the clinical features and
treatment outcomes of patients treated at MDACC between
5/2004 and 6/2012 who fulﬁlled the diagnostic criteria for
MPAL. We identiﬁed a total of 41 patients with a median age
of 47 years (range 9 e 82; 63% male) with characteristics
described in the table below. Twenty one (51%) patients had
leukemia with myeloid plus B-lymphoid (M/B) markers, 18
(44%) with myeloid plus T-lymphoid (M/T) markers, and 2
(5%) with B-lymphoid plus T-lymphoid (B/T) markers. Cyto-
genetic analysis showed 31 patients (76%) had an abnormal
Transplant (n¼16) Chemotherapy (n¼25)
Age, median (range) 42 (19-66) 52 (9-82)
Sex
Male 9 17
Female 7 8
Immunophenotypic Subtypes
B/My 11 10
T/My 4 14
B/T 1 1
Cytogenetic
Diploid 3 7
Complex 6 9
Ph+ 1 3
MLL 2 0
Others 4 6
Induction
Lymphoid 7 13
Myeloid 3 2
Hybrid 6 10
Response
Complete
Remission
12 15
No Response 4 10
Status at Transplant
First Complete
Remission
9 -
Primary Induction
Failure
4 -
Active disease 3 -
Transplant Regimen
Myeloablative 10 -
Reduced Intensity 6 -
Donor
Matched Related 6 -
Matched Unrelated 8 -
Mismatched 2 -
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Sixteen patients received hematopoietic stem cell trans-
plantation (HSCT) in ﬁrst remission (n¼9) or with active
disease (n¼7) following a myeloablative (n¼10) or reduced
intensity (n¼6) conditioning regimen. The median survival
from the time of diagnosis was 19 months (range, 1 e 82
months). On univariate analysis, complete response to
induction therapy was a signiﬁcant predictor of survival (65%
vs. 9%, P < .001). Additionally, there was a trend toward
better overall survival for patients who received HSCT
compared with the patients who were treated with chemo-
therapy alone (60% versus 35%, P ¼ .083). Differences in
immunophenotypic subtypes or karyotype did not impact
the overall survival.
Patients with MPAL represent a rare and heterogeneous
category of leukemia with poor prognosis. The stricter clas-
siﬁcation schema should help to lessen heterogeneity and
allow for better understanding of the leukemia, and ulti-
mately better patient outcomes. Our small series suggests
that response to induction portends better survival.
Furthermore, hematopoietic stem cell transplantation can
further improve outcomes.226
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Background: The current acceptable conditioning regimen
used for hematopoietic stem cell transplantation (HSCT) in
pediatric leukemia consists of total body irradiation (TBI)
especially in acute lymphoblastic leukemia (ALL). Consid-
ering the complications and limitations of TBI-based condi-
tioning regimens, some studies tried to uses non-TBI
conditioning regimens.
Methods: From 1992 to 2012 in a retrospective study from
our center pediatric patients (age <15) with acute myelo-
balstic leukemia (AML) and ALL candidate for HSCT included.
The patients were prepared using a non-radiation-based
conditioning regimen (busulfan/cyclophosphamide in allo-
genic and busulfan/etoposide in autologus). In the allogenic
HSCT, Cyclosporine A and methotrexate were used as graft-
versus-host disease (GvHD) prophylaxis regimen.
Results: Of 268 patients with AML (autologus¼57,
allogenic¼104) and ALL (allogenic¼107), 137(51%) of them
were boys and 131(49%) were girls. The median age at
transplantation were 11years (range: 1-15years) in AML
patients and 12years (range: 0.8-15years) in ALL patients.
With a median follow up of 31 months for AML patients,
overall survival (OS), disease free survival (DFS) for autologus
and allogenic transplantations were 64%, 59.2% and 69%,
61.5% respectively. In ALL patients with a median follow up of
14 months, OS and DFS were 80.3% and 70%. The most
common cause of deaths in both AML and ALL patients was
relapse (63% and 71%). Regarding GVHD occurrence, in AML
and ALL patients 67 (41.6%) and 61 (57%) did experience
acute GVHD. Considering chronic GVHD for AML and ALL
patients, results were 20(12.4%) and 13(12.1%).
Conclusion: Regarding the adverse effects of using TBI-
based conditioning regimen, it seems that in pediatric
patients with AML and ALL using a non-TBI based condi-
tioning regimen can be a good alternative in HSCT. However,
large controlled well-designed studies are needed for further
understanding of differences between TBI and non-TBI
conditioning regimens.227
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Introduction: Optimal sampling interval, sample source and
technique to detect impending relapse after hematopoietic
cell transplantation (HCT) is not well-deﬁned. For most
myeloid malignancies (except CML) donor chimerisms,
peripheral blood parameters, and bone marrow cytomor-
phology are the main options for disease detection post-HCT.
The role of molecular markers is still evolving. The aim of our
study is to evaluate the usefulness of 3 monthly bone
marrow (BM) evaluations for the ﬁrst year after HCT using
these techniques in predicting relapse.
